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Treatment with nucleos(t)ide analogues in chronic hepatitis B:
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Room Ha204, 3015 CE Rotterdam, The NetherlandsSee Article, pages 11–20Despite the introduction of eﬀective vaccination pro-
grams in a substantial number of countries, it is antic-
ipated that in the coming decades many hepatitis B
virus (HBV)-infected patients will die from liver failure
or hepatocellular carcinoma. Eﬀective antiviral therapy
may decrease the incidence of this HBV-related mortal-
ity, which is currently estimated around one million
annually worldwide [1]. Permanent and complete sup-
pression of viral replication is the main treatment goal
of antiviral therapy with nucleos(t)ide analogues (NA)
for chronic HBV infection [2–4]. As a sustained oﬀ-
treatment response seems only possible in a minority
of patients, NA have to be administered for very long
periods, if not indeﬁnitely [5–7]. Development of antivi-
ral resistance is a major limitation to long-term eﬃcacy
of NA. It leads to reversion of virologic and histolog-
ical improvement, and enhances the rate of disease pro-
gression [8]. In the last few years management of
resistance has evolved, and treatment strategies and
clinical guidelines have been developed, which are
focused on prevention of antiviral drug resistance
[4,9,10]. First, only potent NA with a high genetic bar-
rier, meaning drugs requiring multiple resistance muta-
tions, should be used as monotherapy. Second,
treatment should be adapted at an early stage in case
of incomplete viral suppression, as several studies have0168-8278/$36.00  2009 European Association for the Study of the Liver.
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ciated with lower rates of antiviral drug resistance in
HBV patients in the long term [11–13]. The so-called
road map concept and the recently published EASL
guidelines on the treatment of chronic HBV infection
both propose that virologic response should be
assessed at week 12 and 24 to identify primary non-
response and/or partial virologic response, respectively,
and to modify treatment accordingly [4,9]. Although it
is questionable whether this concept also applies to the
new potent drugs with low resistance rates, experts sug-
gested treatment modiﬁcation in patients receiving ten-
ofovir or entecavir with a partial virologic response at
week 48 as well [4]. A third option would be to oﬀer de
novo combination of NA therapy, although the clinical
beneﬁt in HBV-monoinfected patients will be diﬃcult
to demonstrate in light of antiviral drugs with excellent
resistance proﬁles.
In this issue of the Journal of Hepatology, Zeuzem
et al. [14], report on a post-hoc analysis of the two-
year results of the GLOBE trial, to identify the stron-
gest predictor for optimal outcomes at two years of
treatment with telbivudine. Key endpoints are HBV
DNA less than 300 copies/ml, serum ALT normaliza-
tion, HBeAg seroconversion, and telbivudine resis-
tance at week 104. Resistance was deﬁned as
emergence of treatment – associated resistance muta-
tions, identiﬁed by direct sequencing in all patients
with serum HBV DNA >1.000 copies/ml at week
104. Stepwise logistic regression analyses were per-
formed to identify variables associated with treatment
outcomes. The most important message of this study
is that undetectable HBV DNA at week 24 is thePublished by Elsevier B.V. All rights reserved.
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thermore, as previously known from other studies,
low HBV DNA (i.e. <9 log10 copies/ml) and high
ALT levels (i.e. >2 ULN) were associated with
favourable outcomes at year 2 in HBeAg-positive
patients. In HBeAg-negative patients, baseline HBV
DNA and ALT levels were not signiﬁcant predictors
of outcomes at year 2. The study describes an
intent-to-treat analysis and therefore has an advantage
to the entecavir follow-up studies using a suboptimal
design necessitating cumulative conﬁrmed response
and the tenofovir studies where a combination of ten-
ofovir and emtricitabine was given to those not
responding adequately after 72 weeks [15–17]. Zeuzem
et al. do not address the results of their study on tel-
bivudine within the perspective of the outcome of
other recently licensed anti-HBV drugs.
What implications does the outcome of this study on
telbivudine have on our clinical practice? The ﬁrst ques-
tion is whether week 24 is the optimal time point for treat-
ment evaluation of the initial response to telbivudine, and
whether these results can be translated to other NA. The
multivariate logistic regression analyses identiﬁed unde-
tectable HBV DNA at week 24 as the strongest predictor
for all four outcomes at week 104. Yet, one can hardly be
surprised by this outcome. Serum HBV DNA is closely
related to all four study endpoints, and, more impor-
tantly, week 24 is nearer to the time point of outcome
(i.e. week 104) than baseline or week 12. It is likely that
if undetectable HBVDNA at week 36 or 48 were included
in themodel, these parameterswould appear to be a stron-
ger predictor for all outcomes at week 104 than undetect-
able HBV DNA at week 24. This would, however, not
necessarily indicate that week 36 or 48 would be better
time points of evaluation. This is in fact suggested by
the current study where it appears that approximately
30% of the HBeAg-positive patients with detectable
HBVDNAatweek 12 demonstrated resistance to telbivu-
dine atweek 104 [14]. Subsequently,most clinicianswould
probably not wait until week 24 before switching to alter-
nate treatment. With respect to lamivudine which has an
inferior resistance proﬁle as compared to telbivudine, a
recent report showed that HBV DNA levels measured
as early as four weeks were able to predict the ideal
response to lamivudine at ﬁve years of therapy [18]. So
far, no predictors for resistance to either entecavir or ten-
ofovir could be identiﬁed due to their extremely low resis-
tance rates [17,19], which make any of these on-treatment
recommendations unapplicable to antiviral agents with a
high barrier against resistance. Therefore, only extensive
clinical decision analyses will be able to help us to eluci-
date the optimal treatment strategies using on-treatment
serumHBVDNA levels to prevent the emergence of anti-
viral drug resistance in patients receiving NA-therapy.
The second question is whether telbivudine, which
was not given priority as a ﬁrst-line treatment optionin the recent EASL HBV treatment guidelines [4], may
still be a suitable treatment option for patients with
favourable baseline and on-treatment characteristics.
Telbivudine is an L-nucleoside that is highly selective
for HBV [20]. Recently, the two-year results of the
GLOBE-trial, comparing telbivudine to lamivudine
monotherapy in patients with chronic HBV monoinfec-
tion, were presented [21]. In HBeAg-positive patients,
56% of telbivudine-treated subjects achieved undetect-
able HBV DNA, and 30% demonstrated HBeAg-sero-
conversion. In HBeAg-negative patients, 82% of
telbivudine-treated subjects showed HBV DNA levels
less than 300 copies/ml after two years of treatment.
However, the frequency of telbivudine-resistant HBV
(rtM204I) in HBeAg-positive patients increased from
5% at year 1 to 25% at 2 years, whereas in HBeAg-neg-
ative patients 11% demonstrated genotypic resistance to
telbivudine at year 2. The current study shows that in
patients with favourable baseline characteristics and
undetectable HBV DNA at week 24, emergence of tel-
bivudine-resistant mutations still occurred in approxi-
mately 2% of both HBeAg-positive and HBeAg-
negative patients [14]. As compared with entecavir-trea-
ted subjects, genotypic resistance to entecavir developed
in only 1.2% of NA-naı¨ve patients after ﬁve years of
treatment [17]. Moreover, antiviral drug resistance was
not observed in any patient after two years of tenofovir
treatment [19]. As previously mentioned, one can com-
ment on the design of the phase III entecavir and tenofo-
vir studies. Nevertheless, the excellent proﬁles of both
agents have now been conﬁrmed in large-scale investiga-
tor-initiated studies with variable follow-up, organised
by European research consortia [22–24]. Finally, it is
not well known which percentage of patients indeed
meet the criteria of the favourable baseline proﬁle
(HBV DNA <9 log10 copies/ml and ALT levels >2
ULN) for response to telbivudine. The authors state
that recent survey data indicate that patients with such
characteristics predominate in clinical practice, yet only
17% (80/458) of their own HBeAg-positive patients – a
population still highly prevalent in eastern Asia and
northern Europe – qualiﬁed for these criteria.
In conclusion, the current study undoubtedly helps
to identify patients who are likely to achieve a long-
term maintained response to telbivudine therapy. Nev-
ertheless, one could still question whether telbivudine,
due to its inferior resistance proﬁle, should be consid-
ered as an optimal treatment for HBV-monoinfected
patients, even for those with favourable baseline
characteristics and even when virological response will
be evaluated at week 24. Furthermore, we need well-
powered long-term studies, preferably investigator-dri-
ven, to assess the best future strategy with our stron-
gest antiviral agents: long-term monotherapy, add-on
therapy with a road map or de novo combination
therapy.
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